

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Tissue-specific KIF3A expression data for rs11740584 and rs2299007 were retrieved from the GTEx database, analysis release V7 (<https://www.gtexportal.org>). The whole-genome-sequencing data associated with this study are available through GEO accession GSE151706 [<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151706>]. The source data underlying Figs. 1c, 2a-d, 2f, 3a-c, 3e-f, 5a-b, and Supplementary Figures, 1b-c, 2b, 2e, 3a-b, d are provided as a Source data file.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We performed power calculations and choose a sample size to give us a power of at least 95%.
Data exclusions	We established the following exclusion criteria prior to analysis: when replicate values exceeded a coefficient of variation of 10, then the value that maximize the coefficient of variation was removed. We implemented the exclusion criteria on the allele specific PCR analysis (figure 2 panel F) where 2 replicate values from 2 different individuals were removed.
Replication	We analyzed skin cells taken from human subjects and we have incorporated strict methods to insure the identity and validity of these cells. All experiments were done 1-4 times as noted in the figure legends and each point was run in technical triplicates. All attempts of replication were successful except for Supplementary figure 3 panels a and b, where we saw variation between the first 3 repeats and therefore performed a 4 repeat to strength the findings.
Randomization	This is an observational study, randomization is not applicable.
Blinding	This is an observational study, blinding is not applicable.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

n/a	Involved in the study	n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies	<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines	<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology	<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern		

Antibodies

Antibodies used	Keratin 5 (905501, Rabbit polyclonal, Biologend), E-cadherin (180223, Mouse monoclonal IgG1kappa, Life technologies), Claudin 1 (37-4900, Mouse IgG1, Thermofisher Scientific), Ki67 (ab15580, Rabbit polyclonal, Abcam), CD3 (100303, Biologend), Alexafluor 488 anti-rabbit (A-11008, Thermofisher Scientific), Alexafluor 488 (A-11029, Thermofisher Scientific), Alexafluor 594 anti-mouse (A-11032, Thermofisher Scientific).
Validation	All purchased antibodies have been described as suitable and independently validated for immunohistochemistry by the manufacturers. Keratin 5 polyclonal antibody Poly19055 is used for the in vitro examination of human biological samples using immunohistochemistry (IHC) methods for the qualitative identification of Keratin 5. E-cadherin monoclonal antibody reacts with human epithelial cadherin (E-cadherin, uvomorulin, Cell-CAM 120/80), a 120 kDa transmembrane glycoprotein. Claudin 1 antibody is specific for the C-terminal region of the claudin-1 protein. Ki67 Ab15580 antibody is batch tested in ICC/IHC. CD3 antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. To validate specificity of the antibodies for our immunostaining experiments, we ran tissue section samples with no primary but only the appropriate secondary antibody in parallel with primary antibody containing samples in all of our experiments.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	Mouse, F1 of C57Bl/6 and 129 strains, females and males, 6-10 weeks of age. Kif3aK14Δ/Δ mice were maintained on an alternating
--------------------	--

Laboratory animals	12-hour light cycle with food and water ad libitum, the temperature was kept between 70-74F, humidity between 30-70%, and otherwise maintained and handled according to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council).
Wild animals	The study did not involve wild animals.
Field-collected samples	The study did not involve samples collected from the field.
Ethics oversight	All animal procedures were approved by the Institutional Animal Care and Use Committee (Cincinnati Children's Hospital Medical Center).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	The GCPCR-KIF3A cohort includes a total of 56 participants (45 children aged 7 to 17 years old and 11 adults aged 18 to 26 years old) being 25% black and 66% male, from the Greater Cincinnati, Ohio metro area.
Recruitment	We recruited individuals based on genotype for KIF3A SNPs rs11740584 and/or rs2299007. We minimized self-selection bias by inviting all potential subjects with the genotypes of interest to participate and not disclosing to the participants the genetic results as they are not meaningful on an individual level. Since individuals with Atopic Dermatitis could potentially be more likely to participate, we matched the disease status on both genotype groups.
Ethics oversight	The study was approved by the Cincinnati Children's Hospital Medical Center Institutional Review Board under protocol number 2010-0438.

Note that full information on the approval of the study protocol must also be provided in the manuscript.